New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
06:32 EDTPCRXPacira Pharmaceuticals announces FDA approval for Exparel manufacturing
Pacira Pharmaceuticals announced that the FDA approved an additional bulk manufacturing suite, referred to as Suite C, for Exparel. The suite is housed at the company’s Science Center Campus in San Diego, where Exparel is currently manufactured.
News For PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
09:22 EDTPCRXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amira Nature Foods (ANFI), up 8.6%... Stratasys (SSYS), up 3.6%... Magnum Hunter (MHR), up 3%. ALSO HIGHER: Mavenir Systems (MVNR), up 19.1% after Mitel (MITL) agrees to acquire Mavenir Systems for $560M... Athersys (ATHX), up 19.7% following license agreement and collaboration with Chugai... OHR Pharmaceutical (OHRP), up 11.4% following additional positive data from OHR-102 IMPACT study... NXP Semiconductors (NXPI), up 14% following merger agreement with Freescale Semiconductor (FSL). Freescale Semiconductor is up 9.1%... Mast Therapeutics (MSTX), up 7.7% following positive results from Vepoloxamer study. DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.7%... Scorpio Tankers (STNG), down 4.5%. ALSO LOWER: Lumber Liquidators (LL), down 24.2% following CBS' 60 Minutes says that the company is linked to health and safety violations... Aruba Networks (ARUN), down 1.7% after HP (HPQ) confirms deal to acquire Aruba Networks for $24.67... Pacira Pharmaceuticals (PCRX), down 14.4% after receiving complete response letter from FDA for sNDA in use of Exparel... 500.com (WBAI), down 14.4% after announcing that temporary suspension will adversely impact financial results.
06:33 EDTPCRXPacira receives complete response letter from FDA for sNDA in use of Exparel
Subscribe for More Information
February 26, 2015
10:00 EDTPCRXOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
07:43 EDTPCRXPacira downgraded at BofA/Merrill
Subscribe for More Information
06:17 EDTPCRXPacira downgraded to Underperform from Neutral at BofA/Merrill
Subscribe for More Information
February 25, 2015
07:26 EDTPCRXPacira price target raised to $135 from $111 at Brean Capital
Subscribe for More Information
February 24, 2015
06:43 EDTPCRXPacira sees FY15 Exparel revenue $310M-$330M
Subscribe for More Information
06:42 EDTPCRXPacira reports Q4 non-GAAP EPS 35c, consensus 28c
Reports Q4 revenue $61.8M, consensus $62.12M

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use